Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 1,612 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: MDD Clear all
Completed Not applicable Interventional Results available

Adjunctive Treatment of Major Depression Utilizing Auricular Acupuncture

NCT02579343
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Auricular Acupuncture, Sham Auricular Acupuncture + Lexapro
Device · Drug
Lead sponsor
Florida Gulf Coast University
Other
Eligibility
18 Years to 24 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 22, 2026, 8:01 PM EDT
Completed Phase 3 Interventional

Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode

NCT00080314
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
28
States / cities
Tuscaloosa, Alabama • Little Rock, Arkansas • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 22, 2026, 8:01 PM EDT
Completed Phase 3 Interventional

A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression

NCT00130676
View directory record Official record
Conditions
Major Depressive Disorder, Psychotic Disorders
Interventions
Mifepristone, matching placebo
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
23
States / cities
Pico Rivera, California • Riverside, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2012 · Synced Oct 22, 2026, 8:01 PM EDT
Recruiting No phase listed Observational

The Effect of PROSE or Scleral Lenses on Mental Health

NCT07195721
View directory record Official record
Conditions
Depression - Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Boston Sight
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 22, 2026, 8:01 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Multiple Ascending Oral Dose Evaluation of the Safety, Tolerability, and Pharmacokinetics of DSP-1053 and Its Metabolites in Healthy Subjects and in Subjects With Major Depressive Disorder

NCT01774747
View directory record Official record
Conditions
Healthy
Interventions
DSP-1053, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2014 · Synced Oct 22, 2026, 8:01 PM EDT
Recruiting Not applicable Interventional

Investigating the Neural Mechanisms of Repetitive Brain Stimulation With Invasive and Noninvasive Electrophysiology in Humans

NCT05996900
View directory record Official record
Conditions
Major Depressive Disorder, Epilepsy
Interventions
Intracranial electrodes, TMS
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 22, 2026, 8:01 PM EDT
Recruiting Not applicable Interventional

IMST for Dementia Risk Reduction

NCT07349706
View directory record Official record
Conditions
Systolic Blood Pressure, Blood Pressure, Depression - Major Depressive Disorder, Anxiety, Sleep Quality, Physical Function, Cognitive Function
Interventions
Inspiratory Muscle Strength Training High-Resistance, Inspiratory Muscle Strength Training Low-Resistance
Device
Lead sponsor
Florida State University
Other
Eligibility
60 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 8:01 PM EDT
Active, not recruiting Phase 4 Interventional

Predictors of Cognitive Outcomes in Geriatric Depression

NCT05273996
View directory record Official record
Conditions
Major Depressive Disorder, Neuroticism, Cognitive Change, Stress
Interventions
Sertraline, bupropion, desvenlafaxine
Drug
Lead sponsor
David Steffens
Other
Eligibility
65 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 22, 2026, 8:01 PM EDT
Completed Not applicable Interventional

e-Mindfulness for Depression in Older Adults

NCT03922217
View directory record Official record
Conditions
Depression, Mental Health Disorder
Interventions
Mindful My Way
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 22, 2026, 8:01 PM EDT
Completed Phase 3 Interventional

A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA)

NCT00336713
View directory record Official record
Conditions
Depressive Disorder
Interventions
Saredutant (SR48968C), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 13, 2016 · Synced Oct 22, 2026, 8:01 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

NIMH Rhythms and Blues Study: A Prospective Natural History Study of Motor Activity, Mood States, and Bipolar Disorder

NCT05669703
View directory record Official record
Conditions
Bipolar Disorder, Major Depression, Migraine
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
8 Years to 70 Years
Enrollment
1,260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 22, 2026, 8:01 PM EDT
Completed Phase 2 Interventional

Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)

NCT05757791
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Empagliflozin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 22, 2026, 8:01 PM EDT
Terminated Phase 3 Interventional Results available

Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

NCT04000009
View directory record Official record
Conditions
Adjunctive Treatment of Major Depressive Disorder
Interventions
Pimavanserin
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
33
States / cities
Garden Grove, California • Glendale, California • Irvine, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 22, 2026, 8:01 PM EDT
Completed Not applicable Interventional

Study of Technology-assisted Treatment of Adolescent Depression

NCT01582581
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Telephonic CBT, Wait List Control
Behavioral
Lead sponsor
iHope Network, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Farmington, Connecticut • Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 22, 2026, 8:01 PM EDT
Completed Phase 2 Interventional Results available

Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo

NCT04221230
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
NMRA-335140, Placebo
Drug
Lead sponsor
Neumora Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
38
States / cities
Phoenix, Arizona • Bentonville, Arkansas • Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 22, 2026, 8:01 PM EDT
Terminated Not applicable Interventional Results available

Tapering Off Antidepressants

NCT02661828
View directory record Official record
Conditions
Major Depressive Disorder, Anxiety Disorder, Obsessive Compulsive Disorder, Post-Traumatic Stress Disorder
Interventions
Two-Week Antidepressant Taper Regimen, One-Week Antidepressant Taper Regimen
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 22, 2026, 8:01 PM EDT
Active, not recruiting No phase listed Observational

Assessing an EEG Biomarker of Response to TMS for Major Depression

NCT05008198
View directory record Official record
Conditions
Depression
Interventions
Transcranial Magnetic Stimulation
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 22, 2026, 8:01 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Effect of Systemic Inflammation on Emotion and Cognition in Patients With Mood Disorder - A Vaccine Study

NCT03523767
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
S.typhi Injection, Normal Saline Injection
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 22, 2026, 8:01 PM EDT
Completed Phase 2 Interventional Results available

Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents

NCT01731119
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychosis NOS, Autistic Disorder, Asperger Syndrome, Child Development Disorders, Pervasive, Bipolar I Disorder, Bipolar II Disorder, Mood Disorder NOS, Severe Major Depression With Psychotic Features, Single Episode Major Depression Without Psychotic Symptoms, Severe Mood Disorder With Psychotic Features
Interventions
Latuda©
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
6 Years to 19 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 22, 2026, 8:01 PM EDT
Terminated Phase 3 Interventional Results available

SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study

NCT01436175
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate) + Antidepressant
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
140
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 113 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 22, 2026, 8:01 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females

NCT02356107
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
5-hydroxytryptophan and Creatine monohydrate
Drug
Lead sponsor
Perry Renshaw
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Oct 22, 2026, 8:01 PM EDT
Completed Phase 3 Interventional Results available

Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)

NCT00683592
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
vilazodone, placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Newport Beach, California • Bradenton, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2010 · Synced Oct 22, 2026, 8:01 PM EDT
Not yet recruiting Not applicable Interventional

Multi-site Feasibility of an Integrated Treatment for the Biology and Experience of Depression: The MULTIBED Study

NCT07596914
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cognitive Behavioral Therapy (CBT), Whole-Body Hyperthermia
Behavioral · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
San Francisco, California • Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 8:01 PM EDT
Completed Phase 2 Interventional Results available

Improving Therapeutic Learning in Depression: Proof of Concept

NCT02376257
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
250 mg DCS, 100 mg Modafinil, Placebo
Drug
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 22, 2026, 8:01 PM EDT